Friday, March 1, 2024

Noom, Liviniti partner on GLP-1 Companion platform -Dlight News

Digital weight loss company Noom announced its commercial business, Noom for Work, is partnering with Liviniti, a national pharmacy benefit manager, to offer plan sponsors and their employees a digital GLP-1 Companion for chronic weight conditions.

GLP-1s, or glucagon-like peptide-1 receptor agonists, are a class of medications used in the treatment of type 2 diabetes and, more recently, in the management of chronic weight conditions.

Noom’s GLP-1 Companion integrates with PBM processes, offering nutrition guidance and fitness-focused lessons.

Its digital front door and clinical triage identify members whose weight impacts their health, helping direct resources most appropriately to the highest-risk members.

Members who sign up for Noom receive a tailored GLP-1 Companion program when they indicate they take a GLP-1 during onboarding. They will also have access to a protein-tracking tool, customized and interactive mini-courses, fitness-focused lessons and videos for people at all activity levels.

They can also set goals to support successfully tapering off GLP-1s as clinically appropriate as they navigate their weight loss journey.

“Enhancing all our weight loss and obesity care programs with our GLP-1 Companion ensures anyone taking a GLP-1 will now have access to a tailored, integrated program that helps build better, lasting habits with lifestyle, nutrition, exercise and coaching to improve a member’s long-term success while on medication,” Dr. Linda Anegawa, chief of medicine at Noom, said in a statement.


Healthcare stakeholders pointed to the rise of GLP-1 drugs to treat chronic weight issues as one of the key developments in healthcare last year.

In October, Noom announced the expansion of its digital enterprise offering, Noom for Work, to include clinical obesity-management solution Noom Med, which gives individuals access to clinicians with obesity-care training who provide customized weight-loss plans and support for patients in reducing their reliance on GLP-1 medications. 

In 2021, Noom scored a whopping $540 million in Series F funding in 2021 and $58 million just two years earlier.

However, the digital weight-loss company was not immune to the extensive workforce reductions within digital health companies in 2022, and announced two rounds of layoffs that year.

In 2023, the company announced a third round of job cuts, reportedly laying off about a quarter of its coaches. 

Noom has made numerous executive changes and appointments within the past year. 

In July, the company announced its CEO and cofounder, Saeju Jeong, had stepped down after 16 years, but would continue as executive chairman of the board. Geoff Cook was appointed as its new CEO and a member of the company’s board of directors. 

Last month, Noom announced the appointment of a new chief financial officer, general counsel and chief technology officer.

Related Articles

- Advertisement -

Latest Articles

- Advertisement -